ScholarIQanswers from OpenAlex
Myeloproliferative Neoplasms: Diagnosis and Treatment
TopicLeading institutions, researchers & key papers
Myeloproliferative Neoplasms: Diagnosis and Treatment is a topic indexed in ScholarIQ from OpenAlex.
What is known about Myeloproliferative Neoplasms: Diagnosis and Treatment?
ScholarIQrecord summary
This cluster of papers focuses on the molecular pathogenesis, diagnosis, treatment, and prognosis of myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis. It covers topics such as JAK2 and CALR mutations, prognostic scoring systems, ruxolitinib therapy, hematologic response, leukemic transformation, and stem cell transplantation.
How many works does Myeloproliferative Neoplasms: Diagnosis and Treatment have?
ScholarIQindexed works
Myeloproliferative Neoplasms: Diagnosis and Treatment has 121 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Myeloproliferative Neoplasms: Diagnosis and Treatment?
ScholarIQopenalex
The OpenAlex for Myeloproliferative Neoplasms: Diagnosis and Treatment is on the source record.
What are the most-cited papers on Myeloproliferative Neoplasms: Diagnosis and Treatment?
ScholarIQmost cited works
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally, Steven Lane, Brian Ball, Christine Megerdichian, Rachel Okabe, Fátima Al‐Shahrour, Mahnaz Paktinat, J. Erika Haydu, Elizabeth Housman, Allegra M. Lord, Gerlinde Wernig, Michael G. Kharas, Thomas Mercher, Jeffery L. Kutok, D. Gary Gilliland, Benjamin L. Ebert
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, Andrzei Hellmann, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, R. S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, V. Sandor, Hagop M. Kantarjian, For the COMFORT-I investigators
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Maurizio Ferrari, Heinz Gisslinger, Róbert Královics, Laura Cremonesi, Radek C. Skoda, Mario Cazzola
Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target
Rebekka K. Schneider, Ann Mullally, Aurélien Dugourd, Fabian Peisker, Remco M. Hoogenboezem, Paulina M. H. van Strien, Eric M. Bindels, Dirk Heckl, Guntram Büsche, David Fleck, Gerhard Müller‐Newen, Janewit Wongboonsin, Mónica Ventura Ferreira, Victor G. Puelles, Julio Sáez-Rodríguez, Benjamin L. Ebert, Benjamin D. Humphreys, Rafael Kramann
Where is Myeloproliferative Neoplasms: Diagnosis and Treatment research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Myeloproliferative Neoplasms: Diagnosis and Treatment is open access?
ScholarIQopen access share
80%OPEN ACCESS